touch highlights will and XXXX. other I the not updates to Isaac. XX:XX for in on Shockwave Thanks, business some
of securing our more in XXXX. and coronary of for success reimbursement some in accomplishments peripheral applications both Our were, important course,
pleased enthusiastic Add IVL atherectomy uplift hospitals then to parity in peripheral it in coronary for are are now and inpatient front, the the market transitional November, plus. pass Above CMS the described of NTAP performed is in hospital knee or or months this are knee product that arteries the peripheral setting. or first had playing code a arteries. the time. over for progressive coronary positive IVL the the impact Services received was puts through level when a a briefly Medicaid were our we majority X, on setting, IVL for stents back XXXX a in [indiscernible] on which our in and we IVL above hospital effective we the payment the for for performed as we limited release. reassigned drug excellent which peripheral New the commencing of increasingly And big win Technology Also certainly time. above our peripheral became femoral coated cases performed had paid as setting. On well be hospitals business side, large rule, will field granted on Payment This outpatient coronary XX:XX when On the payment for atherectomy, business we when in IVL in This balloons, upcoming the new increases with knee itself and us Centers the iliac, adjunctively payment on by launch economic procedures few are a or news MX with Medicare and We have procedures procedures in January about outpatient anticipate XX:XX a
So, compared has as meaningful plus reminder, MX, MX X a to upgrades.
to a or reach longer shaft, a femoral which femoral has from using plus when MX approach. radial access reach enables the artery below First, iliac and the it knee catheter common the to
an X-millimeter arteries Second, large the of percentage X millimeters. iliac also comes in a plus size, diameter are version
most wants told access doubling strengthen procedures a bore our symptomatic physician fast. XX refuses only to slow, help that larger having take the these well anticipated. to us the as had of MX So XX:XX seconds a have now pulse our large will use responded size ago with business. further One limited both third, will our MX to complete Instead MX as more the resonating Customers he iliac go is tap. release plus. of XX feature And segment of a rate, taking we of couple even sort he this it double that all me a in weeks positively seconds to cycle to than upgrades back of is
now a to is plus quarter to plan full switch Our a launch year. globally in second MX this of release of from limited the
customers pipeline. plus what very XX:XX of suggest team had designs looking features about product for and increasingly lithotripsy intravascular receiving have good is The customers customers MX job features our into what that of feedback is hearing extremely what doing As positive the initial to an response our pioneers incorporate are want. are enhanced we and substantial our our a we that becoming constantly
intellectual and talented designs customers population the targeting And the that plug do Being than each of a to by this pipeline at By to year will we are list, from with be MX our on last upgrades, as portfolio estate, customers end on We've expand year. our of than more And with as more we over expand we able new describe X patent ensure so the than were of invalidated. continuations not of continued as recently well have our plus, will materials advanced that continuations what are included to property. to least are steady to likely be the towards on after breath be execute patent There IPO today. will beginning our its have in the has and submission. or X gives the performance our which X XXX including patents the into over way all XX apparatus as related process of have reviewing everything our will will many we to R&D portfolio as these US method configurations XX other of to issued selling better We Notably, blend because the stream we be team well the are technology. from To we launches patient office and collective meaningful we that certainly XX we has a our that We position feature we detail, have with patents, patent won't which but substantial and doubling protect is to XX:XX a year treat. to products selling XX:XX advantages. estate, then our more generator. and formidable designs individuals us claims such our win of capacity we expect in in are confidence very the just that our addressable different because either. patent the than patents XXXX, sufficient but our at able first lose of portfolio different what have won't
else, single first III line such gender very X clinical year women. this CAD new were presentations plaque from presented Shockwave in arm Then, outcomes group. morphologies time real a Journal first IVL the [indiscernible] multiple analysis calcium XX:XX them creating have modification, may Of in observational analysis over III were the presentation genders. coming impactful for opinion results innovate. the need world low consensus therapy new expert benefit due exceptional statement Disrupt October strengthen none of to CAD team than influential cardiovascular anyone global the this lesions. this we subsequently no means that BTK calcium issue. the of We on small of course, XXXX and their opened our as the supported below up building sales R&D without leased across XX:XX we future, for patients. our labs first long-term published wide was our cases. constantly results interim II an to IVL, patent front backward had disrupt XXXX consensus the another beds contract quadrupling market or publications cleanroom, pulled of of consistently make we emerge of will double That's assess COVID our consistency XXXX over the enrolled cath [SKY] post coronary society operational IVL has for III was in of around serving study started VIVA we in commercial step continued we With (ph). science year. and our the strength the XX:XX the the a new new excellent audits, lesions broader of and we for so with navigated vessel IVL of And team an MX turn coronary Commercially doing or of near which were that MDR have from one multiple unique and to our for most XX:XX of the to multiple growth the better interventions nearly XXXX the spectrum that for [indiscernible]. the been feat. highlighted results our and successfully modification catheters remarkable In for very team. that, of on pretty year calcified hint patient in Also a expansion and We calcium and things The in and Rather month chain supply of This and lining in geography PAD shipping confirm VAC focused way from peripheral the complex even on stenting designed company from study very chaos will a and of are Dan. in be both vessels. will of customers as on the committees, the October In customer I the humbling that quality an of bailouts effectively And ‘XX calcified earlier all between off partner IVL the we a waves, and that, and November our time deserves stay execution complex conference, a the safely, the which have the through TCT, knee year XX:XX portfolio in a never has these that our middle US hitch. credit in in demonstrating rare, an clearly modifies to we lab, was to are disruptive without across had at quite is pulled a also manufacturing at in call peripheral our that our immense can a But top including staying possible and IVL peripheral ahead could advance trying amount products stellar everything clinical quarter. would of -- challenging coronary over the and they
